Home › Therapeutic areas › Neurology › Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (10 companies)

Companies with an active program in Duchenne Muscular Dystrophy.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $489M 2
DYN Dyne Therapeutics MetabolicNeurology Rare 5 NDA Submitted $3.00B 10
FBIO Fortress Biotech DermatologyHematology+4 Rare 1 Approved $61.4M 16
INSM Insmed CardiovascularImmunology+3 Rare 1 Approved $26.7B 15
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $222M 5
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 1 Approved $1.54B 5
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 1 Phase 1 $197M 5
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 4 Approved $1.58B 11
SLDB Solid Biosciences CardiovascularNeurology Rare 1 Phase 3 $695M 6
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $560M 5